Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3528-3535

  Daibata, Masanori ^a   Nemoto, Yuiko ^a   Bandobashi, Kentaro ^a   Kotani, Norihiro ^a   Kuroda, Masayuki ^a   Tsuchiya, Mutsumi ^a   Okuda, Heiwa ^a   Takakuwa, Tetsuya ^b   Imai, Shosuke ^a   Shuin, Taro ^a   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6;

ADOLESCENT; AGED; ANALYTIC METHOD; ARTICLE; B CELL LYMPHOMA; BONE MORPHOGENETIC PROTEIN 6 GENE; BURKITT LYMPHOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MODIFICATION; FEMALE; GENE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION;

BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250751880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2766     Document Type: Article

References (37)

1. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999;286:481-6.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
3. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
4. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20:1-13.
5. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharman S. Characterization of transforming growth factor β1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncogene 1995;11:1615-22.
6. Kim SJ, Letterio J. Transforming growth factor-β signaling in normal and malignant hematopoiesis. Leukemia 2003;17:1731-7.
7. Sebestyen A, Barna G, Nagy K, et al. Smad signal and TGFβ induced apoptosis in human lymphoma cells. Cytokine 2005;30:228-35.
8. Mazur G, Bogunia-Kubik K, Wrobel T, Kuliczkowski K, Lange A. TGF-β1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006;33:145-9.
9. De Caestecker MP, Piek E, Robert AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.
10. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
11. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev 2006;17:29-40.
12. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63.
13. Horvath LG, Henshall SM, Kench JG, et al. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004;59:234-42.
14. Harwick JCH, van den Brink GR, Bleuming SA, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004;126:111-21.
15. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006;25:2666-73.
16. Dai Z, Lakshmanan RR, Zhu WG, et al. Global methyaltion profiling of lung cancer identifies novel methylated genes. Neoplasia 2001;3:314-23.
17. Dai Z, Popkie AP, Zhu WG, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004;23:3521-9.
18. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signaling pathways in lung cancer. Br J Cancer 2005;93:949-52.
19. Tamada H, Kitazawa R, Gohji K, Kamidono S, Maeda S, Kitazawa S. Molecular cloning and analysis of the 5′-flanking region of the human bone morphogenetic protein-6 (BMP-6). Biochim Biophys Acta 1998;1395:247-51.
20. Drexler HG. Guide to leukemia-lymphoma cell lines. Braunschweig; 2005. p. 118-497.
21. Al Saati T, Delecluze HJ, Chittal S, et al. A novel human lymphoma cell line (Deglis) with dual B/T phenotype and gene rearrangements and containing Epstein-Barr virus genome. Blood 1992;80:209-16.
22. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
23. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-4.
24. Daibata M, Taguchi T, Nemoto Y, et al. Epstein-Barr virus (EBV)-positive pyothorax-associated lymphoma (PAL): chromosomal integration of EBV in a novel CD2-positive PAL B-cell line. Br J Haematol 2002;117:546-57.
25. Hamdy FC, Autzen P, Robinson MC, Horne CHW, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 inhuman benign and malignant prostatic tissue. Cancer Res 1997;57:4427-31.
26. Detmer K, Steele TA, Shoop MA, Dannawi H. Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietic cell lines. Blood Cells Mol Dis 1999;25:310-23.
27. Kersten C, Dosen G, Myklebust JH, et al. BMP-6 inhibits human bone marrow B lymphopoiesis - up regulation of Id1 and Id3. Exp Hematol 2006;34:72-81.
28. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
29. Ide H, Yoshida T, Matsumoto N, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997;57:5022-7.
30. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004;316:100-6.
31. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004;64:8276-84.
32. KIP1. Biochem Biophys Res Commun 2001;285:773-81.
33. Kim IY, Lee DH, Lee DK, et al. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitibity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Res 2003;9:6046-51.
34. Kawamura C, Kizaki M, Yamato K, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 2000;96:2005-11.
35. Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptois of multiple myeloma cells. Blood 2001;97:516-22.
36. Ro TB, Holt RU, Brenne AT, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004;23:3024-32.
37. Fukuda N, Saitoh M, Kobayashi N, Miyazono K. Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction inmyeloma and B-cell hybridoma cells. Oncogene 2006;25:3509-17.